Journey Medical Corp (DERM) Stock Analysis and Metrics

Journey Medical

NASDAQ: DERM

$6.19 ▼ -0.39 (-5.93%)

At close: Jul 24, 2026 · 4:00 PM UTC

Financial Ratios

Market Cap169.02 Mn

P/E-17.66

P/S2.64

Div. Yield0.00

Total Debt (Qtr)25.37 Mn

Revenue Growth (1y) (Qtr)21.17

Add ratio to table…

About

Journey Medical Corporation is a commercial stage pharmaceutical company that focuses on the sale and marketing of FDA approved prescription drugs for dermatological conditions in the United States. The company was incorporated in Delaware in 2014 and maintains its executive offices in Scottsdale Arizona. It is a controlled subsidiary of Fortress Biotech Inc. Journey Medical acquires rights to products and product candidates through licensing or other arrangements funds development and commercializes them through its field sales organization.

The company generates revenue primarily from the sale of its portfolio of FDA approved prescription drugs including Emrosi Qbrexza Accutane Amzeeq Zilxi and legacy products such as Exelderm Targadox Luxamend and the forthcoming anti itch product. It also receives royalty and milestone payments from licensing agreements such as the arrangement with Cutia Therapeutics (HK) Limited for the supply of Amzeeq in China. Additional revenue comes from upfront payments and milestone payments received under licensing out agreements such as the Maruho license for Qbrexza in Asian markets and the Cutia license for Amzeeq and Zilxi in Greater China. These licensing arrangements provide the company with non dilutive cash inflows that complement its product sales revenue.

The company operates in a competitive dermatology market that includes large and midsize players such as Galderma Laboratories Almirall Leo Pharma Mayne Pharma Botanix Pharmaceuticals and Ortho Dermatologics. Its competitive advantages derive from the commercial leadership of its management team which has over 135 years of collective sales and marketing experience and has launched brands that generated over three billion dollars in aggregate peak sales. The company also benefits from an experienced field sales force that covers more than eighty percent of dermatologists in the top fifty U. S. metropolitan statistical areas and reaches over seventy percent of the overall dermatology prescribing market. Journey Medical maintains a specialized distribution network that includes more than six hundred specialty pharmacies and wholesalers allowing it to deliver products directly to prescribers and patients. Several of its products Emrosi Qbrexza Amzeeq and Zilxi are protected by patents listed in the FDA Orange Book providing exclusivity and barriers to generic entry. The firm pursues an active business development strategy that seeks licensing acquisition and partnership opportunities to expand its pipeline and geographic reach.

The company sells its products to specialty pharmacies independent wholesalers distributors retail drug store chains independent pharmacies and managed care organizations such as health maintenance organizations group purchasing organizations nursing homes clinics pharmacy benefit management companies and mail order customers. It also supplies Cutia Therapeutics (HK) Limited for distribution in China and receives royalties on those sales. Additionally Journey Medical has a manufacturing and supply agreement with Epic Pharma LLC for the product Targadox although Epic Pharma acts as a supplier rather than an end user.

Investment Thesis

▲ Bull case

Journey Medical is positioned to capture significant market share in the rosacea treatment segment as AAMROCI (Amrozi) gains traction through superior clinical differentiation and expanding formulary access, with management noting that the product’s rapid onset of action, superior skin clearing effects, and placebo-like safety profile are driving strong patient retention, evidenced by a refill-to-new-prescription ratio approaching 1.5-to-1, up from 1-to-1 at the end of 2025, indicating increasing patient loyalty and satisfaction that supports sustainable organic growth beyond initial prescriptions.
The company has secured pricing agreements with all three major PBM-owned group purchasing organizations (Zynq Health, MSR, and Ascent), which collectively cover approximately 85% of commercial lives in the United States, translating to over 169 million lives with access to Amrozi, and while only about 34% of commercial lives (roughly 60 million) currently have single-step-or-better coverage, management is in deep and advanced discussions with national formularies to improve tier positioning and reduce utilization controls, signaling a clear path to meaningful revenue conversion as coverage quality improves, which could unlock substantial upside in average selling price and prescription volume without proportional increases in sales and marketing spend.
Journey Medical’s disciplined cost structure is enabling operating leverage, as total net product revenues grew 21% year-over-year in Q1 FY26 while operating expenses rose just 6%, and the company delivered positive adjusted EBITDA of $600,000 in the quarter compared to a negative $900,000 in the prior year, with CFO Joseph Benesch noting that excluding a one-time $1.3 million non-cash inventory write-down related to the QBREXZA acquisition, gross margin would have been approximately 69%, reflecting a favorable product mix and scalability that supports sustained profitability as Amrozi scales and legacy products like QBREXZA contribute steady cash flow.
The planned addition of up to two new niche dermatology products later in 2026, coupled with the expansion of the sales force from 35 to 40 representatives (with new hires trained in June and field-ready by July), is strategically timed to complement Amrozi’s growth trajectory without diverting focus, as Claude Maraoui explicitly stated these products will be “pulsed into the third position” and will not alter compensation or promotional emphasis on the top two brands, allowing for incremental revenue contribution from the base business while maintaining Amrozi as the primary growth driver.
Third-party validation from published Phase 3 efficacy and safety results in JAMA Dermatology, endorsement by the National Rosacea Society’s updated treatment algorithms, and anticipated up to three new journal publications in 2026 are strengthening Amrozi’s clinical credibility with payer decision-makers, increasing the likelihood of favorable formulary placement and reducing reliance on co-pay bridging programs, which management believes will enhance net pricing power and improve long-term health economic outcomes that resonate with value-based purchasing trends in managed care.

Journey Medical is positioned to capture significant market share in the rosacea treatment segment as AAMROCI (Amrozi) gains traction through superior clinical differentiation and expanding formulary access, with management noting that the product’s rapid onset of action, superior skin clearing effects, and placebo-like safety profile are driving strong patient retention, evidenced by a refill-to-new-prescription ratio approaching 1.5-to-1, up from 1-to-1 at the end of 2025, indicating increasing patient loyalty and satisfaction that supports sustainable organic growth beyond initial prescriptions.
The company has secured pricing agreements with all three major PBM-owned group purchasing organizations (Zynq Health, MSR, and Ascent), which collectively cover approximately 85% of commercial lives in the United States, translating to over 169 million lives with access to Amrozi, and while only about 34% of commercial lives (roughly 60 million) currently have single-step-or-better coverage, management is in deep and advanced discussions with national formularies to improve tier positioning and reduce utilization controls, signaling a clear path to meaningful revenue conversion as coverage quality improves, which could unlock substantial upside in average selling price and prescription volume without proportional increases in sales and marketing spend.
Journey Medical’s disciplined cost structure is enabling operating leverage, as total net product revenues grew 21% year-over-year in Q1 FY26 while operating expenses rose just 6%, and the company delivered positive adjusted EBITDA of $600,000 in the quarter compared to a negative $900,000 in the prior year, with CFO Joseph Benesch noting that excluding a one-time $1.3 million non-cash inventory write-down related to the QBREXZA acquisition, gross margin would have been approximately 69%, reflecting a favorable product mix and scalability that supports sustained profitability as Amrozi scales and legacy products like QBREXZA contribute steady cash flow.
The planned addition of up to two new niche dermatology products later in 2026, coupled with the expansion of the sales force from 35 to 40 representatives (with new hires trained in June and field-ready by July), is strategically timed to complement Amrozi’s growth trajectory without diverting focus, as Claude Maraoui explicitly stated these products will be “pulsed into the third position” and will not alter compensation or promotional emphasis on the top two brands, allowing for incremental revenue contribution from the base business while maintaining Amrozi as the primary growth driver.
Third-party validation from published Phase 3 efficacy and safety results in JAMA Dermatology, endorsement by the National Rosacea Society’s updated treatment algorithms, and anticipated up to three new journal publications in 2026 are strengthening Amrozi’s clinical credibility with payer decision-makers, increasing the likelihood of favorable formulary placement and reducing reliance on co-pay bridging programs, which management believes will enhance net pricing power and improve long-term health economic outcomes that resonate with value-based purchasing trends in managed care.

▼ Bear case

Despite Journey Medical’s progress in securing GPO contracts, the company has not yet achieved meaningful quality coverage, with Ramsey Alloush disclosing that only about 34% of the 190 million commercial lives in the U.S. (approximately 60 million) currently have access to Amrozi with a single-step-or-better prior authorization or step edit requirement, indicating that the vast majority of covered lives still face significant utilization barriers that limit actual prescribing and reimbursement, and management’s expectation of “good news throughout 2027” suggests a delayed timeline for formulary improvements that could constrain near-term revenue acceleration despite strong prescription volume trends.
The company’s gross margin of 61% in Q1 FY26 was depressed by a $1.3 million non-cash charge related to a write-down of API inventory from the 2021 QBREXZA acquisition, and while management claims this is a one-time item, the persistence of such adjustments raises concerns about the long-term viability of legacy product inventory management and the potential for recurring non-cash charges that could distort true profitability, especially as QBREXZA has been demoted from a first-line to second-line promotional position, signaling weakening commercial momentum and potential obsolescence risk in a competitive dermatology landscape.
Journey Medical’s reliance on increasing the refill-to-new-prescription ratio as a proxy for patient satisfaction and loyalty may be misleading, as the absolute number of new prescriptions for Amrozi grew only modestly from 26,000 in Q1 FY25 to 30,000 in Q1 FY26 — a 15% increase — suggesting that growth is being driven more by increased refills among existing users than by robust new patient acquisition, which could indicate market saturation among early adopters and a lack of broad-based appeal beyond a niche segment of dermatologists and patients already familiar with the product.
The planned launch of up to two new niche dermatology products later in 2026 introduces execution risk, as Claude Maraoui acknowledged that these products will require tactical programs such as direct messaging to Oracea patients and switching trials involving free drug samples, which will increase SG&A expenses in the second half of the year, and with the sales force expansion timed for July deployment, the full cost impact will hit during the critical back-half period, potentially offsetting any incremental revenue and delaying the path to sustained profitability if uptake is slower than anticipated.
While management expresses confidence in achieving positive EBITDA for the remainder of 2026 and beyond, the company reported a GAAP net loss of $2.2 million in Q1 FY26, and with no formal guidance provided for the full year, there remains significant uncertainty about whether the operating leverage from Amrozi’s growth will be sufficient to overcome fixed costs, especially if payer reimbursement improvements lag behind expectations or if competitive pressures from generic doxycycline or emerging therapies erode pricing power before Amrozi achieves broad formulary dominance.

Despite Journey Medical’s progress in securing GPO contracts, the company has not yet achieved meaningful quality coverage, with Ramsey Alloush disclosing that only about 34% of the 190 million commercial lives in the U.S. (approximately 60 million) currently have access to Amrozi with a single-step-or-better prior authorization or step edit requirement, indicating that the vast majority of covered lives still face significant utilization barriers that limit actual prescribing and reimbursement, and management’s expectation of “good news throughout 2027” suggests a delayed timeline for formulary improvements that could constrain near-term revenue acceleration despite strong prescription volume trends.
The company’s gross margin of 61% in Q1 FY26 was depressed by a $1.3 million non-cash charge related to a write-down of API inventory from the 2021 QBREXZA acquisition, and while management claims this is a one-time item, the persistence of such adjustments raises concerns about the long-term viability of legacy product inventory management and the potential for recurring non-cash charges that could distort true profitability, especially as QBREXZA has been demoted from a first-line to second-line promotional position, signaling weakening commercial momentum and potential obsolescence risk in a competitive dermatology landscape.
Journey Medical’s reliance on increasing the refill-to-new-prescription ratio as a proxy for patient satisfaction and loyalty may be misleading, as the absolute number of new prescriptions for Amrozi grew only modestly from 26,000 in Q1 FY25 to 30,000 in Q1 FY26 — a 15% increase — suggesting that growth is being driven more by increased refills among existing users than by robust new patient acquisition, which could indicate market saturation among early adopters and a lack of broad-based appeal beyond a niche segment of dermatologists and patients already familiar with the product.
The planned launch of up to two new niche dermatology products later in 2026 introduces execution risk, as Claude Maraoui acknowledged that these products will require tactical programs such as direct messaging to Oracea patients and switching trials involving free drug samples, which will increase SG&A expenses in the second half of the year, and with the sales force expansion timed for July deployment, the full cost impact will hit during the critical back-half period, potentially offsetting any incremental revenue and delaying the path to sustained profitability if uptake is slower than anticipated.
While management expresses confidence in achieving positive EBITDA for the remainder of 2026 and beyond, the company reported a GAAP net loss of $2.2 million in Q1 FY26, and with no formal guidance provided for the full year, there remains significant uncertainty about whether the operating leverage from Amrozi’s growth will be sufficient to overcome fixed costs, especially if payer reimbursement improvements lag behind expectations or if competitive pressures from generic doxycycline or emerging therapies erode pricing power before Amrozi achieves broad formulary dominance.

Segments Breakdown of Revenue (2025)

Peer Comparison

Companies in the Drug Manufacturers - Specialty & Generic

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	HLN	Haleon plc	88.07 Bn	103.29	6.00	11.45 Bn
2	TEVA	Teva Pharmaceutical Industries Ltd	35.75 Bn	23.02	2.06	16.63 Bn
3	ZTS	Zoetis Inc.	31.84 Bn	12.05	3.35	9.05 Bn
4	TAK	Takeda Pharmaceutical Co Ltd	27.18 Bn	-10.29	0.59	28.76 Bn
5	UTHR	UNITED THERAPEUTICS Corp	23.09 Bn	17.93	7.28	-
6	RDHL	RedHill Biopharma Ltd.	21.32 Bn	2,931.66	2.24	-
7	VTRS	Viatris Inc	19.96 Bn	-67.32	1.37	14.34 Bn
8	NBIX	Neurocrine Biosciences Inc	17.66 Bn	26.41	5.69	-

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password